Cyclic AMP-related and cation-affected human platelet chloride transport regulation.
Cystic fibrosis has been characterized as a defect in the regulation of cyclic AMP-dependent transepithelial chloride transport. The activation of cyclic AMP-dependent protein kinase A by cyclic AMP occurs normally in cystic fibrosis cells, but they fail to transport chloride ions in response to protein kinase A stimulation. Defective chloride secretion and abnormal electrolyte transport occurs in several organs including the lung, sweat glands, intestine and pancreas. The present work was aimed at exploring whether the same or similar regulatory systems are functional in platelets, and if they are altered or deficient in individuals with cystic fibrosis. Chloride transport in platelets from normal subjects and from cystic fibrosis patients was measured by cell sizing techniques where chloride permeability is the limiting factor. In platelets from healthy volunteers, the chloride channel blocker, 5-nitro-2-(3-phenylpropylamino) benzoic acid, inhibits the transport in a dose-dependent manner. The preservation of chloride transport capability is shown to be dependent upon the presence of either Ca2+ or two divalent cation substitutes, Cd2+ or Cu2+. It is also shown that in normal subjects 0.1 mumol/l prostaglandin E1, which elevates cyclic AMP 6 times and abolishes platelet aggregation, significantly enhances the rate constant of the transport. Furthermore, in five out of nine cystic fibrosis patients studied, platelet chloride transport did not respond to stimulation by prostaglandin E1.
Agam
G
G
Unit of Clinical Biochemistry, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Aviram
M
M
Zilberman-Kaufman
M
M
Rothstein
A
A
Livne
A A
AA
D000293:Adolescent; D000527:Alprostadil / Q000494:pharmacology; D001792:Blood Platelets / Q000378:metabolism*; D002412:Cations / Q000494:pharmacology*; D002648:Child; D002675:Child, Preschool; D018118:Chloride Channels / Q000037:antagonists & inhibitors / Q000097:blood*; D000242:Cyclic AMP / Q000097:blood*; D003550:Cystic Fibrosis / Q000097:blood*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000097:blood; D004533:Egtazic Acid / Q000494:pharmacology; D005260:Female; D006096:Gramicidin / Q000494:pharmacology; D006801:Humans; D008297:Male; D008670:Metals / Q000494:pharmacology; D009579:Nitrobenzoates / Q000494:pharmacology
C505032:CFTR protein, human; D002412:Cations; D018118:Chloride Channels; D008670:Metals; D009579:Nitrobenzoates; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D006096:Gramicidin; C058176:5-nitro-2-(3-phenylpropylamino)benzoic acid; D004533:Egtazic Acid; D000242:Cyclic AMP; D000527:Alprostadil